Merz
Trending Articles
Related Content
Manufacturing
Licence and co-development agreement signed to develop botulinum toxin in Japan
Teijin announced it has signed an exclusive licence and co-development agreement with Merz Pharma for Xeomin (incobotulinumtoxinA), the novel type A botulinum neurotoxin, covering all expected indications for ethical pharmaceutical use in Japan